Guardant Health Appoints Craig Eagle, MD as Chief Medical Officer
03 May 2021 - 10:05PM
Business Wire
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, announces the appointment of Craig Eagle, MD as the
company’s new Chief Medical Officer (CMO).
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210503005041/en/
Dr. Craig Eagle, MD (Photo: Business
Wire)
As CMO, Dr. Eagle will play a vital role in furthering Guardant
Health’s mission of transforming cancer care by unlocking data that
will accelerate precision oncology for patients at all stages of
the disease. “I am thrilled to welcome Dr. Craig Eagle, a respected
leader in oncology, as our Chief Medical Officer,” said AmirAli
Talasaz, Guardant Health President. “Craig has a wealth of
experience driving medical affairs, clinical development, and
clinical trial operations at leading pharmaceutical companies, and
he will undoubtedly make a great impact as we continue to develop
and commercialize first-in-class products and scale the company for
the future.”
“I look forward to contributing to the ground-breaking work
Guardant Health is doing to serve unmet medical needs by applying
precision oncology across the continuum of cancer care,” said Craig
Eagle, MD. “Guardant Health is uniquely positioned to serve cancer
patients at all stages of the disease, from advanced to early-stage
cancers. I look forward to joining the team as the company
continues to increase patient access to potentially life-changing
diagnostics and testing.”
Prior to joining Guardant Health, Dr. Eagle has most recently
served as Vice President of Medical Affairs Oncology for Genentech
where he oversaw the medical programs across the oncology
portfolio, and developed innovative cancer trials and strategies in
personalized health care. Prior to Genentech, Dr. Eagle has held
several positions in the U.S. and internationally over his 19-year
career at Pfizer including global head of the Oncology Medical and
Outcomes Group. In this role, he oversaw the worldwide medical
programs and development of numerous commercially successful drugs.
Dr. Eagle currently serves on the Board of Directors for Generex
Biotechnology and NuGenerex Immuno-Oncology.
Dr. Eagle attended medical school at the University of New South
Wales in Sydney, Australia and received his general internist
training at Royal North Shore Hospital in Sydney. Dr. Eagle
completed his specialist training in hemato-oncology and laboratory
hematology at Royal Prince Alfred Hospital in Sydney and was
granted Fellowship in the Royal Australasian College of Physicians
(FRACP) and the Royal College of Pathologists Australasia
(FRCPA).
About Guardant Health
Guardant Health is a leading precision oncology company focused
on helping conquer cancer globally through use of its proprietary
blood tests, vast data sets, and advanced analytics. The Guardant
Health oncology platform leverages capabilities to drive commercial
adoption, improve patient clinical outcomes and lower healthcare
costs across all stages of the cancer care continuum. Guardant
Health has commercially launched liquid biopsy-based Guardant360®,
Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer
patients, and Guardant Reveal™ test for early-stage cancer
patients. These tests fuel development of its LUNAR screening
program, which aims to address the needs of asymptomatic
individuals eligible for cancer screening and individuals at a
higher risk for developing cancer with early detection.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of federal securities laws, including statements
regarding the potential scope, impact or benefit of Guardant Health
liquid biopsies which involve risks and uncertainties that could
cause the actual results to differ materially from the anticipated
results and expectations expressed in these forward-looking
statements. These statements are based on current expectations,
forecasts and assumptions, and actual outcomes and results could
differ materially from these statements due to a number of factors.
These and additional risks and uncertainties that could affect
Guardant Health’s financial and operating results and cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release include those
discussed under the captions “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operation” and elsewhere in its Annual Report on Form 10-K for the
year ended December 31, 2020 as well as in its other reports filed
with the Securities and Exchange Commission, including, when filed,
its Quarterly Report on Form 10-Q for the period ended March 31,
2021. The forward-looking statements in this press release are
based on information available to Guardant Health as of the date
hereof, and Guardant Health disclaims any obligation to update any
forward-looking statements provided to reflect any change in its
expectations or any change in events, conditions, or circumstances
on which any such statement is based, except as required by law.
These forward-looking statements should not be relied upon as
representing Guardant Health’s views as of any date subsequent to
the date of this press release.
Source: Guardant Health, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210503005041/en/
Investor Contact: Carrie Mendivil
investors@guardanthealth.com
Media Contact: Anna Czene press@guardanthealth.com
Julie Johnson julie.johnson@uncappedcommunications.com
Guardant Health (NASDAQ:GH)
Historical Stock Chart
From Apr 2024 to May 2024
Guardant Health (NASDAQ:GH)
Historical Stock Chart
From May 2023 to May 2024